The Effects of Mindfulness Meditation on Hallucination and Delusion in Severe Schizophrenia Patients with More Than 20 Years’ Medical History
Sheng Jia-ling,Yan,Xianghong Yang,Ti‐Fei Yuan,Donghong Cui
DOI: https://doi.org/10.1111/cns.13067
2018-01-01
CNS Neuroscience & Therapeutics
Abstract:Mindfulness meditation alleviates symptoms of distress, pain, and many chronic diseases.1-3 In schizophrenic patients, mindfulness intervention leads to better psychosocial functioning,4 improved positive emotions,5 and reduced negative symptoms.6 It is unknown if mindfulness meditation could reduce positive symptoms in the chronic schizophrenia patients. Five male patients, averaged age at 55.80 ± 9.45 years old (ranged 44-66 years), with averaged medical history of 30.20 ± 8.53 years (ranged 21-41 years) were recruited for present study. All patients received active antipsychotics treatment upon admission (at higher doses than patients on average): chlorpromazine equality averaged at 670.00 ± 176.47 mg/d (ranged 487.5-900). These patients demonstrated severe and drug treatment-resistant hallucination/delusions (score >5; Details in Table 1). The Positive and Negative Syndrome Scale (PANSS), Short Form-36 Health Survey (SF-36), and Five Facet Mindfulness Questionnaire (FFMQ) were measured by an expert clinical psychologist. The study has been approved by the ethic committee of medical research in the Minzheng hospital, and written informed consents were obtained from all patients for the study, or the guardians/next of kin of these participants when in need. Informed consent was as well obtained for the publication of this case report. This clinical trial has been registered on the Chinese Clinical Trial Registry (https://www.chictr.org.cn/index.aspx). The registration number is ChiCTR-OOB-17014038. Registered December 19, 2017 (retrospectively registered). Timeline: February 2017: Recruitment of patients and start of the trial. Intervention: 8 months, group intervention, and individual training. Follow-up: 1, 2, 3, 4, 5, 6, 7, 8 weeks and 8 months after start point of intervention for the hallucination and delusion symptoms, and relevant scales. Mindfulness meditation was performed with following procedures. In the first 8 weeks, the group intervention (90 minutes each, led by two experienced tutors) was conducted per week, and after the period, the group intervention frequency was once per month. During the continuous 8 months period, the patients performed mindfulness meditation per day for 20-40 minutes. The records were double checked and confirmed by the tutors. The data were analyzed with SPSS 18.0 software (SPSS Inc., Chicago, IL, USA); paired-sample t test was used for differences before and after intervention. The hallucination and delusion symptoms persisted and exhibited no change during the past 8 years (measured at 8 years ago, 4 years ago, 2 weeks ago, and baseline time point) prior to this study. Following mindfulness training intervention, the hallucination and delusion symptoms did not exhibit much change in the first 2 weeks but began to decrease after 3 weeks of intervention. The improvements persisted as the intervention continued. At the end of 8-month intervention period, significant reductions in both hallucination and delusion symptoms were observed in all patients (P < 0.05; Figure 1). Notably, the PANSS positive symptoms and negative symptoms both decreased following intervention (P < 0.05; Table 2). In addition, the quality of life index in SF-36 and mindfulness score in FFMQ improved significantly following intervention (P < 0.05; Table 3). In present study, we reported the effectiveness of 8-month mindfulness meditation intervention in five severe schizophrenia patients with more than 20 years’ medical history. There are several potential mechanisms underlying the interventional effects of mindfulness meditation on hallucination and delusion. First, mindfulness meditation produces brain oscillation changes and increases brain network integration,7 which could contribute to the decreased abnormal brain activities and reduced hallucination/delusion. Second, mindfulness training increases acceptance and ameliorates anxiety/distress emotion, resulting in general improvement in psychotic symptoms. In the future, it will be important to investigate the meditation-evoked brain changes to further elucidate the potential mechanisms of the benefits from intervention. One limitation of the current study, however, is the small sample size and the lack of a proper control. Larger randomized clinical trials are yet required to confirm the efficacy of mindfulness training in treatment of chronic schizophrenia patients. In conclusion, our results demonstrated the promising potential of mindfulness meditation on the management of severe chronic schizophrenia patients. The study is supported by National Key R&D Program of China (2017YFC0909200); the National Natural Foundation of China (81671336); SJTU Joint Medical and Engineering Funding (YG2016ZD06), and SJTU Joint Art and Science Funding (14JCRZ05); Shanghai Key laboratory of Psychotic Disorders (13dz2260500). The funds provide support for research materials used in present study. The authors declare no conflict of interest.